by Richard Daverman, PhD
September 9, 2013 -- DelMar Pharma and Guangxi Wuzhou Pharma have formed a China clinical advisory board to oversee trials of their cancer treatment, which is known as VAL-083 or “DAG for Injection.” The drug is already approved in China for leukemia and lung cancer. The two companies are working together to gain China approval for VAL-083 as a treatment for glioblastoma multiforme, the most aggressive form of brain cancer, and global approval for all indications. More details....
Stock Symbol: (OTCQB: DMPI)
Help employers find you! Check out all the jobs and post your resume.
